ASH 2022 | Impact of age on toxicity & outcomes in patients with LBCL treated with CD19-directed CAR-T therapy
Abu-Sayeef Mirza, MD, MPH, Yale University, New Haven, CT, describes the structure and results from a retrospective analysis evaluating the impact of age on the outcomes of patients with large B-cell lymphoma (LBCL) after being treated with CD19-directed CAR-T therapy. This analysis demonstrated that patients aged 65 years old and above represented a larger proportion of patients in the real-world database compared to the initial registration trials. Ultimately, age was not found to play a significant role in patient survival, although older patients were found to show higher rates of neurotoxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
